17.3 Acute Delirium, Encephalopathy & Severe Confusion

ABFM Family Medicine Certification Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making

1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care

2 Chapter 2: Healthcare Systems, Practice Management & Quality

2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination

3 Chapter 3: Ethics, Law, Biostatistics & Health Equity

3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism

4 Chapter 4: Lifestyle Counseling & Behavior Change

4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling

5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention

5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling

6 Chapter 6: Routine Adult Immunizations

6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise

7 Chapter 7: Pediatric Health Maintenance & Surveillance

7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride

8 Chapter 8: Behavioral Health & Safety Screening

8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling

9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic

9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening

10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic

10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling

11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate

11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making

12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception

12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C

13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care

13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam

14 Chapter 14: Emergent Cardiovascular Conditions

14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies

15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises

15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management

16 Chapter 16: Vascular & Thromboembolic Emergencies

16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion

17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness

17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion

18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies

18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies

19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies

19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice

20 Chapter 20: Acute Pulmonary & Airway Emergencies

20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction

21 Chapter 21: Acute Traumatic Injuries & Wound Care

21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites

22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies

22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises

23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies

23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection

24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies

24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis

25 Chapter 25: Hematologic, Urologic & Dental Emergencies

25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma

26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies

26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia

27 Chapter 27: Acute Head, Neck & Neurologic Symptoms

27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring

28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms

28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis

29 Chapter 29: Acute Upper Respiratory Tract Infections

29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion

30 Chapter 30: Acute Lower Respiratory Infections & Cough

30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia

31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions

31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation

32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms

32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation

33 Chapter 33: Acute Upper Gastrointestinal Conditions

33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness

34 Chapter 34: Acute Lower Gastrointestinal Conditions

34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani

35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders

35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes

36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders

36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis

37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions

37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation

38 Chapter 38: Acute Infectious Dermatoses

38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum

39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses

39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma

40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries

40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains

41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries

41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes

42 Chapter 42: Acute Ambulatory Fractures & Dislocations

42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation

43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls

43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients

44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain

44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies

45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions

45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction

46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions

46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation

47 Chapter 47: Acute Women's Health & Early Pregnancy Care

47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder

48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination

48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis

49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections

49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses

50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia

50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT

51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases

51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy

52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD

52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria

53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus

53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance

54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases

54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition

55 Chapter 55: Chronic Endocrine Disorders

55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders

56 Chapter 56: Chronic Kidney Disease & Venous Disorders

56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD

57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases

57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy

58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care

58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders

59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders

59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome

60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders

60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care

61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders

61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness

62 Chapter 62: Chronic Psychiatric Disorders

62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder

63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions

63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating

64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation

64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy

65 Chapter 65: Chronic Dermatologic Conditions

65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus

66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care

66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control

67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit

67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit

17.3 Acute Delirium, Encephalopathy & Severe Confusion

Key Takeaways Explain This Topic AI

Delirium is an acute, fluctuating neurocognitive disorder characterized by disturbances in attention, awareness, and cognition; its three motoric subtypes are hypoactive (~50%, somnolence and psychomotor slowing, most frequently overlooked and carrying the highest mortality), hyperactive (~25%, psychomotor agitation and hallucinations), and mixed (~25%).

Diagnostic confirmation requires the Confusion Assessment Method (CAM): Feature 1 (Acute onset and fluctuating course) AND Feature 2 (Inattention) must BOTH be present, alongside EITHER Feature 3 (Disorganized thinking) OR Feature 4 (Altered level of consciousness).

Etiologic evaluation requires a systematic search using the DELIRIUM or I WATCH DEATH framework, prioritizing occult infections (UTI, pneumonia, sepsis), metabolic derangements (hyponatremia, hypercalcemia, hypoglycemia, uremia, hepatic encephalopathy), high-risk medications (anticholinergics, sedatives, opioids), and acute withdrawal.

Wernicke encephalopathy is an acute neurocognitive emergency caused by thiamine (vitamin B1) deficiency, presenting with the classic triad of encephalopathy, oculomotor dysfunction (horizontal nystagmus, bilateral abducens palsy), and gait ataxia; intravenous thiamine (500 mg TID) must ALWAYS be administered BEFORE or concurrently with intravenous dextrose solutions to avoid precipitating irreversible brainstem necrosis and Korsakoff amnestic syndrome.

First-line management of delirium is strictly non-pharmacologic (multicomponent Hospital Elder Life Program [HELP] interventions: frequent reorientation, sensory aids, sleep-wake hygiene, early mobilization, removal of Foley catheters and physical restraints); pharmacotherapy (low-dose haloperidol or quetiapine) is reserved exclusively for severe agitation posing an immediate physical danger, while benzodiazepines are strictly contraindicated (worsen and prolong delirium) unless treating alcohol or sedative withdrawal.

Last updated: September 2026

Definition, Neurobiology & Clinical Phenomenology of Delirium

Delirium is a severe, acute neuropsychiatric syndrome characterized by concurrent disturbances of attention, awareness, and baseline cognition. It affects 15% to 50% of hospitalized older adults, up to 80% of mechanically ventilated intensive care unit (ICU) patients, and is associated with substantial increases in hospital-acquired complications, institutionalization, accelerated long-term cognitive decline, and a 2- to 4-fold increase in in-hospital mortality .

DSM-5 Diagnostic Criteria for Delirium

To establish a definitive diagnosis of delirium, the patient must fulfill all five criteria (A through E) :

Criterion A : A disturbance in attention (reduced ability to direct, focus, sustain, and shift attention) and awareness (reduced orientation to the environment).

Criterion B : The disturbance develops over a short period of time (typically hours to a few days), represents an acute change from baseline attention and awareness, and tends to fluctuate in severity during the course of a day.

Criterion C : An additional disturbance in cognition (memory deficit, disorientation, language impairment, visuospatial ability, or perceptual disturbance).

Criterion D : The disturbances in Criteria A and C are not better explained by another pre-existing, established, or evolving neurocognitive disorder and do not occur in the context of a severely reduced level of arousal, such as coma.

Criterion E : Evidence from the history, physical examination, or laboratory findings that the disturbance is a direct physiological consequence of another medical condition , substance intoxication or withdrawal, exposure to a toxin, or multiple etiologies.

Pathophysiological Mechanisms & Neurotransmitter Imbalance

Delirium is the clinical manifestation of acute global cerebral microvascular failure and neuronal metabolic breakdown triggered by systemic stressors. Key mechanisms include:

Neuroinflammation : Peripheral infection, tissue trauma, or surgical stress triggers massive release of systemic pro-inflammatory cytokines (IL-1β, IL-6, TNF-α). These cytokines compromise blood-brain barrier permeability, activate cerebral microglia, and induce neurotoxic neuroinflammation.

Cholinergic Deficiency & Dopaminergic Excess : The neurochemical final common pathway of delirium involves a profound central cholinergic deficit (acetylcholine is essential for attention, vigilance, and memory encoding) coupled with a relative excess of central dopamine and noradrenaline (mediating psychomotor agitation, hyperarousal, and hallucinations). Medications with anticholinergic properties directly induce delirium by blocking central muscarinic receptors.

Oxidative Stress & Cellular Energy Failure : Hypoxemia, ischemia, and hypoglycemia disrupt cerebral ATP generation, leading to glutamate excitotoxicity and astrocyte swelling.

Differential Diagnosis: Delirium vs Dementia vs Depression

Clinical Domain Delirium Dementia (Major Neurocognitive Disorder) Depression (Pseudodementia)
Onset Acute (hours to days) Insidious (months to years) Subacute to insidious (weeks to months)

Course Fluctuating ; prominent nocturnal worsening ("sundowning"); lucid intervals Slowly progressive; stable across days Relatively stable; diurnal variation (worse mood in mornings)

Attention / Focus Severely impaired ; highly distractible; unable to sustain or shift focus Intact in early-to-moderate stages; impaired only in end-stage disease Preserved; may show reduced effort ("I don't know" responses)

Level of Consciousness Altered / Fluctuating (lethargic, vigilant, stuporous) Clear and alert until severe terminal stages Completely intact and clear

Cognitive Features Fragmented, disorganized thinking, immediate memory loss Impaired short-term and long-term memory; preserved attention Intact cognitive testing when urged; psychomotor slowing

Perceptual Disturbances Common; vivid visual and tactile hallucinations, persecutory delusions Uncommon until advanced stages (except visual hallucinations in Lewy Body Dementia) Rare; mood-congruent depressive delusions (guilt, poverty)

Reversibility Highly reversible if underlying precipitant is rapidly treated Generally irreversible (progressive neurodegeneration) Reversible with pharmacotherapy and psychotherapy

Motoric Subtypes of Delirium

Delirium is classified into three distinct motoric subtypes based on psychomotor activity and arousal level: MOTORIC SUBTYPES OF DELIRIUM

┌────────────────────────────────────────────────────────────────────────┐
│ 1. HYPOACTIVE DELIRIUM (~50% of cases) — THE "QUIET KILLER" │
│ • Clinical Presentation: Somnolence, lethargy, psychomotor slowing, │
│ decreased spontaneous speech, apathy, staring into space, withdrawal │
│ • Diagnostic Pitfall: FREQUENTLY MISSED or misdiagnosed as depression, │
│ fatigue, or "a pleasant, cooperative patient" │
│ • Prognosis: HIGHEST IN-HOSPITAL MORTALITY; high rates of pressure │
│ ulcers, aspiration pneumonia, DVT, and prolonged hospitalization │
└────────────────────────────────────────────────────────────────────────┘
│
┌───────────────────────────────────┴────────────────────────────────────┐
│ 2. HYPERACTIVE DELIRIUM (~25% of cases) │
│ • Clinical Presentation: Psychomotor agitation, restlessness, combative│
│ behavior, wandering, emotional lability, hypervigilance, screaming, │
│ vivid visual hallucinations, pulling at IV lines and Foley catheters │
│ • Easily recognized by nursing and clinical teams; lowest mortality │
└────────────────────────────────────────────────────────────────────────┘
│
┌───────────────────────────────────┴────────────────────────────────────┐
│ 3. MIXED DELIRIUM (~25% of cases) │
│ • Clinical Presentation: Unpredictable fluctuations between hyperactive│
│ and hypoactive states within a single 24-hour cycle │
│ • Classically presents with daytime somnolence and quiet lethargy │
│ alternating with nocturnal psychomotor agitation ("sundowning") │
└────────────────────────────────────────────────────────────────────────┘
Diagnostic Assessment: The Confusion Assessment Method (CAM)

The Confusion Assessment Method (CAM) is the validated clinical reference standard for diagnosing delirium at the bedside, with a sensitivity of 94% to 100% and specificity of 90% to 95% .

The CAM Diagnostic Algorithm

To confirm a clinical diagnosis of delirium, the patient must fulfill Feature 1 AND Feature 2 , alongside EITHER Feature 3 OR Feature 4 :

Delirium = Feature 1 + Feature 2 + (Feature 3 OR Feature 4)

Feature 1: Acute Onset and Fluctuating Course :

Is there evidence of an acute change in mental status from the patient's baseline?

Does the abnormal behavior fluctuate during the day (e.g., coming and going, or increasing in severity at night)?

Assessment : Collateral history from family members, primary caregivers, or bedside nursing staff is mandatory.

Feature 2: Inattention :

Did the patient have difficulty focusing attention (e.g., easily distracted, unable to keep track of what was being said)?

Bedside Testing : Digit span testing (inability to repeat 5 digits forward or 3 digits backward); spelling the word "WORLD" backwards (normal: D-L-R-O-W); reciting the months of the year backwards (December to July); or counting backwards from 20 to 1.

Feature 3: Disorganized Thinking :

Was the patient's thinking disorganized, rambling, or incoherent? Was the conversation illogical, or did they shift unpredictably between unrelated subjects?

Feature 4: Altered Level of Consciousness :

Overall, how would you rate the patient's level of consciousness?

Any state OTHER THAN "ALERT" fulfills this criterion: Vigilant (hyperalert, startled by minor stimuli), Lethargic (drowsy, easily aroused by verbal stimulus but drifts off), Stuporous (difficult to arouse, requires vigorous or repeated tactile/painful stimulus), or Comatose (unresponsive).

Delirium Assessment in the ICU: CAM-ICU

In intubated, mechanically ventilated patients who cannot speak, the CAM-ICU utilizes the Richmond Agitation-Sedation Scale (RASS) to assess consciousness (Feature 4: RASS other than 0), and the Attention Screening Examination (ASE) : the clinician recites 10 letters ("S-A-V-E-A-H-A-A-R-T") and instructs the patient to squeeze their hand on the letter "A"; >2 errors indicates inattention (Feature 2).

Systematic Etiologic Investigation: DELIRIUM & I WATCH DEATH

Delirium is never a standalone primary diagnosis; it is an emergency neurobehavioral manifestation of an underlying medical illness. Delirium results from the interaction of predisposing factors (baseline vulnerability: age ≥ 65, pre-existing dementia, functional dependency, sensory impairment, malnutrition) and precipitating factors (acute noxious insults).

The "DELIRIUM" Diagnostic Framework THE "DELIRIUM" ETIOLOGICAL FRAMEWORK

┌───┬────────────────────────────────────────────────────────────────────┐
│ D │ DRUGS & MEDICATIONS (Most Common Reversible Precipitant) │
│ │ • Anticholinergics (diphenhydramine, hydroxyzine, oxybutynin, TCAs)│
│ │ • Sedative-hypnotics (benzodiazepines, zolpidem, "Z-drugs") │
│ │ • Opioids (especially meperidine, codeine, high-dose morphine) │
│ │ • Corticosteroids, fluoroquinolones, H2-blockers, polypharmacy (≥5)│
├───┼────────────────────────────────────────────────────────────────────┤
│ E │ ELECTROLYTE & METABOLIC DERANGEMENTS │
│ │ • Hyponatremia (<130 mEq/L) or hypernatremia (>150 mEq/L) │
│ │ • Hypercalcemia, hypokalemia, hypomagnesemia │
│ │ • Hypoglycemia (<50 mg/dL) or severe hyperglycemia (DKA / HHS) │
│ │ • Uremic encephalopathy, Hepatic encephalopathy (elevated ammonia) │
├───┼────────────────────────────────────────────────────────────────────┤
│ L │ LACK OF DRUGS (ACUTE WITHDRAWAL) │
│ │ • Alcohol withdrawal (Delirium Tremens - autonomic instability) │
│ │ • Benzodiazepine or barbiturate withdrawal │
├───┼────────────────────────────────────────────────────────────────────┤
│ I │ INFECTION (Occult Sepsis) │
│ │ • Urinary tract infection / pyelonephritis (most common in elderly)│
│ │ • Pneumonia, sepsis, bacteremia, cellulitis, C. difficile colitis │
│ │ • CNS infections: Meningitis, viral encephalitis │
├───┼────────────────────────────────────────────────────────────────────┤
│ R │ REDUCED SENSORY INPUT / ENVIRONMENTAL STRESS │
│ │ • Missing eyeglasses or hearing aids (sensory deprivation) │
│ │ • Sleep deprivation, ICU psychosis, frequent room transfers │
├───┼────────────────────────────────────────────────────────────────────┤
│ I │ INTRACRANIAL PATHOLOGY │
│ │ • Acute ischemic stroke, intracerebral hemorrhage │
│ │ • Subdural hematoma (occult fall in anticoagulated elderly patient)│
│ │ • Non-convulsive status epilepticus (NCSE), brain metastasis │
├───┼────────────────────────────────────────────────────────────────────┤
│ U │ URINARY RETENTION & FECAL IMPACTION │
│ │ • Severe bladder distension (post-void residual >300 mL) │
│ │ • Severe obstipation/impaction triggering massive sympathetic surge│
├───┼────────────────────────────────────────────────────────────────────┤
│ M │ MYOCARDIAL & PULMONARY HYPOXIA / HYPERCAPNIA │
│ │ • Acute myocardial infarction (frequently "silent" in elderly) │
│ │ • Pulmonary embolism, acute decompensated heart failure │
│ │ • Severe hypoxemia (PaO2 <60 mm Hg) or hypercapnia (CO2 narcosis) │
└───┴────────────────────────────────────────────────────────────────────┘
The "I WATCH DEATH" Systematic Mnemonic

Used globally in emergency and internal medicine rotations:

I - Infection : UTI, pneumonia, sepsis, meningitis.

W - Withdrawal : Alcohol, benzodiazepines, barbiturates.

A - Acute metabolic : Electrolytes, acid-base, hepatic/uremic encephalopathy.

T - Trauma : Subdural hematoma, hip fracture, burns.

C - CNS pathology : Stroke, hemorrhage, tumor, seizure.

H - Hypoxia / Hypercapnia : COPD exacerbation, PE, carbon monoxide.

D - Deficiencies : Thiamine (Wernicke), vitamin B12, folate, niacin.

E - Endocrine : Thyroid storm, myxedema coma, adrenal crisis, DKA.

A - Acute vascular : Shock, hypertensive emergency, dissecting aneurysm.

T - Toxins / Drugs : Prescriptions, illicit substances, anticholinergics.

H - Heavy metals : Lead, mercury, arsenic, environmental toxins.

Standard Diagnostic Workup Algorithm

Bedside Immediate : Capillary blood glucose, continuous pulse oximetry, 12-lead ECG (silent ischemia, long QTc), bladder ultrasound scan (rule out acute urinary retention).

STAT Serum & Urine Laboratory Testing : CBC with differential, Comprehensive Metabolic Panel (sodium, potassium, BUN, creatinine, AST, ALT, total bilirubin, albumin), serum calcium, magnesium, phosphorus, urinalysis with microscopy and culture , blood cultures × 2, venous or arterial blood gas.

Toxicology & Medication Review : Urine drug screen, serum alcohol level, serum acetaminophen/salicylate, serum digoxin/lithium/phenytoin levels if prescribed.

Neuroimaging (Non-Contrast Head CT) : Indicated if: new focal neurological deficit, history of recent fall or head trauma, unexplained fever with altered mental status, active anticoagulant therapy, or failure to identify an extracranial cause.

Lumbar Puncture : Mandatory if fever, nuchal rigidity, meningismus, new rash, or unexplained encephalopathy in an immunocompromised host.

Wernicke Encephalopathy & Korsakoff Syndrome

Wernicke encephalopathy (WE) is a hyperacute, life-threatening neurological emergency caused by an absolute or relative deficiency of thiamine (vitamin B1) . If untreated, mortality approaches 20% , and 85% of survivors develop irreversible Korsakoff syndrome .

Pathophysiology & Enzymatic Cofactors

Thiamine pyrophosphate (TPP) is an indispensable coenzyme for four fundamental enzymes involved in cerebral glucose and carbohydrate metabolism:

Pyruvate Dehydrogenase : Links glycolysis to the citric acid (Krebs) cycle;
Alpha-Ketoglutarate Dehydrogenase : Krebs cycle intermediate oxidation;

Transketolase : Rate-limiting enzyme of the pentose phosphate pathway (synthesizes NADPH and ribose-5-phosphate for myelin and glutathione maintenance);

Branched-Chain Alpha-Ketoacid Dehydrogenase .

When thiamine is depleted, cellular ATP synthesis halts, lactic acid accumulates, intracellular glutamate surges (excitotoxicity), and blood-brain barrier breakdown occurs. Characteristic histopathology: symmetric petechial hemorrhages, astrocytosis, and neuronal necrosis localized to the mamillary bodies, periaqueductal gray matter, walls of the third and fourth ventricles, and cerebellar vermis .

Populations at High Risk

Chronic Alcohol Use Disorder : Most common cause. Alcohol directly inhibits active intestinal thiamine transport, impairs hepatic thiamine storage, and suppresses phosphorylation of thiamine into active TPP.

Severe Malnutrition & Hyperemesis : Prolonged starvation, anorexia nervosa, hyperemesis gravidarum, bariatric/gastric bypass surgery, bowel obstruction, prolonged intravenous fluid administration lacking multivitamin supplementation, systemic advanced cancer, and end-stage renal disease on dialysis.

The Classic Clinical Triad THE WERNICKE ENCEPHALOPATHY CLINICAL TRIAD

┌────────────────────────────────────────────────────────────────────────┐
│ 1. ENCEPHALOPATHY / CONFUSION │
│ • Profound global confusion, severe inattention, apathy, somnolence, │
│ and spatial/temporal disorientation │
├────────────────────────────────────────────────────────────────────────┤
│ 2. OCULOMOTOR DYSFUNCTION │
│ • Bilateral HORIZONTAL NYSTAGMUS (most common early ocular sign) │
│ • Bilateral LATERAL RECTUS PALSY (Abducens nerve, Cranial Nerve VI) │
│ • Conjugate gaze palsies, sluggish pupillary light reactions, ptosis │
├────────────────────────────────────────────────────────────────────────┤
│ 3. GAIT ATAXIA │
│ • Broad-based, unsteady, cerebellar gait ataxia; inability to walk or │
│ stand unassisted due to cerebellar vermis and vestibular dysfunction │
└────────────────────────────────────────────────────────────────────────┘

Critical Diagnostic Rule : The complete clinical triad is present in only 16% to 33% of patients . Clinicians must maintain a high index of suspicion: any patient with alcohol dependence or severe malnutrition presenting with ANY ONE of these components (acute confusion, nystagmus, or ataxia) must be treated presumptively for Wernicke encephalopathy .

THE CARDINAL CLINICAL MANDATE: THIAMINE BEFORE DEXTROSE

The Biochemical Hazard : Intravenous administration of glucose or dextrose solutions (e.g., 5% dextrose in water [D5W]) to a thiamine-depleted individual fuels glycolysis. Rapid glycolysis instantly consumes the trace remaining thiamine cofactors in pyruvate dehydrogenase, precipitating catastrophic brainstem metabolic collapse, acute mamillary body necrosis, irreversible coma, and death.

Treatment Protocol :

Administer Intravenous Thiamine 500 mg TID (infused in 100 mL 0.9% normal saline over 30 minutes) BEFORE OR CONCURRENTLY WITH ANY INTRAVENOUS DEXTROSE INFUSION .

Continue high-dose IV thiamine 500 mg IV every 8 hours for at least 3 to 5 consecutive days , followed by 250 mg IV daily for 3 to 5 days, then transition to oral thiamine (100 mg daily indefinitely).

Always administer concurrent intravenous magnesium sulfate (1 to 2 grams IV) ; magnesium is an obligatory cofactor for thiamine pyrophosphokinase. Thiamine administration will fail if hypomagnesemia is uncorrected.

Korsakoff Amnestic Syndrome

The chronic, irreversible sequela of untreated or undertreated Wernicke encephalopathy secondary to selective necrosis of the mamillary bodies and medial dorsal thalamic nuclei.

Characterized by profound anterograde amnesia (inability to acquire new episodic memories) and retrograde amnesia with temporal gradient, paired with confabulation (the spontaneous unconscious fabrication of memories to compensate for memory voids, without intent to deceive) and total lack of insight ( anosognosia ). Intellectual function and long-term remote memories remain largely preserved.

Non-Pharmacologic Management: The First-Line Foundation

Non-pharmacologic multicomponent environmental interventions represent the gold-standard, first-line therapy for all patients with delirium . The landmark Hospital Elder Life Program (HELP) demonstrated that standardized non-pharmacologic protocols reduce delirium incidence by 40% and shorten hospital length of stay.

Core Non-Pharmacologic Interventions (HELP Model)

Cognitive Reorientation & Environmental Support :

Frequent verbal reorientation by staff and family (state patient's name, current location, date, reason for hospitalization).

Large-print whiteboards in direct visual line showing date, day of week, and name of assigned nurse.

Visible wall clocks and calendars; familiar personal items and family photographs at bedside.

Maintain daytime natural light exposure (open window blinds); dim lighting at night.

Consolidate nighttime vital sign checks, phlebotomy, and medication administrations to provide an uninterrupted 4-hour sleep block .

Sensory Adaptation :

Ensure the patient's clean prescription eyeglasses and functioning hearing aids (verified with working batteries) are in place immediately upon waking. Sensory deprivation dramatically triggers disorientation and visual hallucinations.

Early Mobilization & Functional Activity :

Ambulation out of bed at least three times daily; sit upright in a chair for all meals.

Active range-of-motion physical therapy exercises for bedbound individuals.

Hydration & Nutritional Support :

Encourage oral fluid intake hourly; monitor volume status; assist with meal feeding; ensure clean, properly seated dental prostheses.

Removal of Iatrogenic Tethers :

Promptly remove indwelling Foley urinary catheters (catheters represent a foreign body, restrict mobility, promote bacteremia, and provoke severe agitation; replace with intermittent straight catheterization or external collection devices).

Discontinue unneeded IV lines, telemetry cables, and pulse oximeter probes.

STRICT AVOIDANCE OF PHYSICAL RESTRAINTS :

Physical restraints (wrist ties, vest restraints) do NOT prevent falls or tube dislodgement; they exacerbate panic, provoke extreme combative agitation, prolong delirium duration, double in-hospital mortality, and risk fatal strangulation.

Guideline alternative: Constant 1-on-1 bedside observation ("patient safety attendant" / sitter) .

Pharmacologic Management: Strict Indications & High-Risk Pitfalls
Core Clinical Guideline Principles

Antipsychotics do NOT treat, prevent, or resolve delirium . High-quality randomized controlled trials (MIND, REDUCE) show that antipsychotics do not shorten delirium duration, reduce ICU length of stay, or decrease mortality.

Strict Indications : Pharmacotherapy is reserved strictly as a last-resort rescue for patients exhibiting severe, refractory agitation, psychosis, or combative behavior that poses an immediate, serious physical danger to the patient or staff, or directly threatens life-sustaining medical equipment (e.g., extubating endotracheal tube, pulling central venous line or dialysis catheter), when aggressive non-pharmacologic de-escalation has failed.

Pharmacological Regimens for Severe Agitation

Medication Recommended Dosing Mechanism / Pharmacokinetics High-Yield Clinical Pearls & Hazards

Haloperidol (First-Generation High-Potency) 0.5 to 1.0 mg PO or IV/IM ;; Repeat every 30–60 min as needed;; Maximum 5 mg/24 hours in elderly Potent dopamine D2 receptor antagonist.; Onset: 10–20 min IV; 30–60 min IM. Minimal anticholinergic activity; does NOT suppress respiration or cause hypotension.; Hazard : Prolongs QTc interval; obtain baseline ECG. Discontinue if QTc > 500 ms (risk of Torsades de Pointes). Can induce acute dystonia or extrapyramidal symptoms (EPS).

Quetiapine (Second-Generation Atypical) 12.5 to 25 mg PO BID or at bedtime;; Titrate up to 50–100 mg/day max Low-affinity D2 antagonist; 5-HT2A antagonist; moderate H1 sedation. DRUG OF CHOICE IN PARKINSON'S DISEASE & LEWY BODY DEMENTIA due to negligible dopamine-2 blockade and minimal EPS. Somnolence and orthostatic hypotension are primary side effects.

Olanzapine (Second-Generation Atypical) 2.5 to 5.0 mg PO / ODT or IM ;; Maximum 10 mg/day Antagonist at 5-HT2A, D2, H1, and alpha-1 receptors. Available as orally disintegrating tablet (ODT) or IM injection. Moderate anticholinergic activity; causes sedation and metabolic shifts.

Risperidone (Second-Generation Atypical) 0.25 to 0.5 mg PO BID;; Maximum 2 mg/day Potent D2 and 5-HT2A antagonist. Low anticholinergic burden. Higher incidence of extrapyramidal symptoms at doses >2 mg/day.

FDA Black Box Warning & Deprescribing Mandate

Black Box Warning : All first- and second-generation antipsychotics carry an FDA black box warning for an increased risk of all-cause mortality (primarily ischemic stroke and cardiovascular death/aspiration pneumonia) when administered to elderly patients with dementia-related psychosis.

Immediate Deprescribing : Antipsychotics must be prescribed at the lowest effective dose for the shortest possible duration, and must be tapered and discontinued immediately once severe agitation resolves (within 24 to 48 hours). Never discharge a patient home on an antipsychotic initiated solely for hospital delirium.

THE BENZODIAZEPINE CONTRAINDICATION: A Lethal Clinical Mistake

Strict Rule : Benzodiazepines (e.g., lorazepam, diazepam, alprazolam, midazolam) are strictly contraindicated in the routine management of delirium .

Pathophysiological Rationale : Benzodiazepines enhance GABA-mediated central inhibition, which paradoxically causes severe behavioral disinhibition, worsening confusion, daytime somnolence, increased fall risk, and doubles the duration of delirium.

THE ONLY TWO CLINICAL EXCEPTIONS :

Delirium Tremens (Alcohol Withdrawal Delirium) ;

Sedative-Hypnotic (Benzodiazepine / Barbiturate) Withdrawal .

In these specific withdrawal syndromes, intravenous benzodiazepines administered under symptom-triggered validated protocols (e.g., CIWA-Ar) are the lifesaving treatment of choice.